Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)

NCT01484496 is registered in ClinicalTrials.gov with Human Genome Sciences Inc., a GSK Company as lead sponsor.

NCT NCT01484496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01484496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Phase
Phase 3
Overall status
Completed
Start date
November 16, 2011
Completion date
October 1, 2015
Enrollment
839 (actual)
Sites
207

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus